Telaprevir to Boceprevir Switch Highlights Lack of Cross-ReactivityCARLSON, Amanda; GREGORICH, Zachery; STRIKER, Rob et al.Clinical infectious diseases. 2013, Vol 56, Num 4, pp 552-554, issn 1058-4838, 3 p.Article

Quels traitements pour le futur ? = Future treatmentsPAWLOTSKY, Jean-Michel.Hépato-gastro (Montrouge). 2010, Vol 17, pp 51-60, issn 1253-7020, 10 p., SUP5Article

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical TrialsSULLIVAN, James C; DE MEYER, Sandra; MARTIN, Emily C et al.Clinical infectious diseases. 2013, Vol 57, Num 2, pp 221-229, issn 1058-4838, 9 p.Article

Pharmacokinetic Interaction between Telaprevir and MethadoneHEESWIJK, Rolf Van; VERBOVEN, Peter; VANDEVOORDE, Ann et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 5, pp 2304-2309, issn 0066-4804, 6 p.Article

Characterization of Telaprevir Treatment Outcomes and Resistance in Patients With Prior Treatment Failure: Results From the REALIZE TrialDE MEYER, Sandra; DIERYNCK, Inge; PICCHIO, Gaston et al.Hepatology (Baltimore, Md.). 2012, Vol 56, Num 6, pp 2106-2115, issn 0270-9139, 10 p.Article

Traitement de l'hépatite C chronique = Treatment of chronic hepatitis CFONTAINE, Hélène; SOGNI, Philippe; POL, Stanislas et al.Hépato-gastro (Montrouge). 2011, Vol 18, Num 5, pp 461-469, issn 1253-7020, 9 p.Conference Paper

Anite érosive sous tétaprévir = Perianal ulcerations with telaprevirAWWAD, A; RENARD, P; POUZOULET, J et al.Annales de dermatologie et de vénéréologie. 2012, Vol 139, Num 5, pp 391-392, issn 0151-9638, 2 p.Article

Review and Management of Drug Interactions With Boceprevir and TelaprevirKISER, Jennifer J; BURTON, James R; ANDERSON, Peter L et al.Hepatology (Baltimore, Md.). 2012, Vol 55, Num 5, pp 1620-1628, issn 0270-9139, 9 p.Article

Influence of ITPA Polymorphisms on Decreases of Hemoglobin During Treatment with Pegylated Interferon, Ribavirin, and TelaprevirSUZUKI, Fumitaka; SUZUKI, Yoshiyuki; IKEDA, Kenji et al.Hepatology (Baltimore, Md.). 2011, Vol 53, Num 2, pp 415-421, issn 0270-9139, 7 p.Article

Telaprevir for Chronic Hepatitis C with Genotype 1: A Meta-AnalysisDANG, Shuang-Suo; WANG, Wen-Jun; WANG, Xiu-Fang et al.Hepato-gastroenterology. 2012, Vol 59, Num 114, pp 461-468, issn 0172-6390, 8 p.Article

Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?PASCALE, Alina; SERFATY, Lawrence.Journal of hepatology. 2013, Vol 58, Num 2, pp 391-394, issn 0168-8278, 4 p.Article

Rash sous télaprévir: quelle prise en charge ? : Foie et Peau = A rash under telaprevir, how to manage?DUPIN, N; MILPIED, B; ALLANORE, L et al.La Lettre de l'hépato-gastroentérologue. 2012, Vol 15, Num 3, pp 135-139, issn 1286-580X, 5 p.Article

Les nouveaux traitements de l'hépatite C = New treatments for hepatitis C virus infectionSOGNI, P.Images en dermatologie. 2012, Vol 5, Num 1, pp 27-29, issn 1964-4167, 3 p.Article

Rash sous télaprévir: quelle prise en charge? = A rash under telaprevir, how to manage?DUPIN, N; MILPIED, B; ALLANORE, L et al.Images en dermatologie. 2012, Vol 5, Num 1, pp 30-34, issn 1964-4167, 5 p.Article

Emergence of Telaprevir-Resistant Variants Detected by Ultra-Deep Sequencing After Triple Therapy in Patients Infected With HCV Genotype 1AKUTA, Norio; SUZUKI, Fumitaka; SAITOH, Satoshi et al.Journal of medical virology. 2013, Vol 85, Num 6, pp 1028-1036, issn 0146-6615, 9 p.Article

Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis CKLIBANOV, Olga M; WILLIAMS, Shannon H; SMITH, Lisa S et al.Pharmacotherapy. 2011, Vol 31, Num 10, pp 951-974, issn 0277-0008, 24 p.Article

Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis CSMITH, Lisa S; NELSON, Michael; NAIK, Sagar et al.The Annals of pharmacotherapy. 2011, Vol 45, Num 5, pp 639-648, issn 1060-0280, 10 p.Article

Racemic N-sulfonyloxaziridines as highly diastereoselective enolate hydroxylating agents: enantioselective synthesis of (2S,3S)-3-amino-N-cyclopropyl-2-hydroxyhexanamideKISS, Eleonóra; MARKO, István E; GUILLAUME, Michel et al.Tetrahedron (Oxford. Print). 2011, Vol 67, Num 47, issn 0040-4020, 8955, 9173-9178 [7 p.]Article

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevirSUZUKI, Fumitaka; SUZUKI, Yoshiyuki; SAITO, Satoshi et al.Journal of clinical virology. 2010, Vol 47, Num 1, pp 76-78, issn 1386-6532, 3 p.Article

Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionJACOBSON, Ira M; MCHUTCHISON, John G; GEORGE, Jacob et al.The New England journal of medicine. 2011, Vol 364, Num 25, pp 2405-2416, issn 0028-4793, 12 p.Article

Telaprevir: A Hepatitis C NS3/4A Protease InhibitorMATTHEWS, Samuel James; LANCASTER, Jason W.Clinical therapeutics. 2012, Vol 34, Num 9, pp 1857-1882, issn 0149-2918, 26 p.Article

Drug Rash with Eosinophilia and Systemic Symptoms due to TelaprevirMONTAUDIE, H; PASSERON, T; CARDOT-LECCIA, N et al.Dermatology (Basel). 2010, Vol 221, Num 4, pp 303-305, issn 1018-8665, 3 p.Article

Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?PONS, Sarah Talavera; LAMBLIN, Geraldine; BOYER, Anne et al.European journal of clinical pharmacology. 2014, Vol 70, Num 7, pp 775-789, issn 0031-6970, 15 p.Article

Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysisPARK, C; JIANG, S; LAWSON, K. A et al.Journal of clinical pharmacy and therapeutics (Print). 2014, Vol 39, Num 1, pp 14-24, issn 0269-4727, 11 p.Article

Hépatite C: comment traiter le patient cirrhotique (naïf ou en échec de traitement) ? = Hepatitis C: how to treat cirrhotic patients, treatment-naïve or treatment-experienced?COSTENTIN, C; HEZODE, C.La Lettre de l'infectiologue. 2013, Vol 28, Num 6, pp 209-214, issn 0296-9009, 6 p.Article